Table 2.
Outcome summary by treatment group
| Buspirone | Placebo | Measure of Treatment Effect | ||||
|---|---|---|---|---|---|---|
| Variable | Estimate | Estimate | Description | Estimate | Standard Error | p-value |
| Urine Drug Screens for Cannabis | ||||||
| Mean (SD) % Negative, ITT (all missed assumed positive) | 20.3% (32.5%) | 6.5% (16.2%) | Wilcoxon Rank Sum Test | N/A | N/A | 0.13 |
| Mean (SD) % Negative, only observed specimens | 27.6% (40.9%) | 11.7% (27.8%) | Wilcoxon Rank Sum Test | N/A | N/A | 0.16 |
| Model-based estiamte % negative{a} | 28.8% | 11.0% | Risk Difference | 17.8% | 9.9% | 0.07 |
| Timeline Follow-Back | ||||||
| % Days reporting no use{a} | 45.2% | 51.4% | Risk Difference | −6.2% | 10.4% | 0.55 |
| % Reduced days using relative to baseline{b} | 69.6% | 85.2% | Fisher's exact | N/A | N/A | 0.30 |
| % Reduced amount using/using day relative to baseline{b} | 91.3% | 92.6% | Fisher's exact | N/A | N/A | 1.00 |
| Hamilton Anxiety Rating Scale, mean (SD){d} | ||||||
| Total score | −6.10 (7.11) | −4.00 (5.68) | Wilcoxon Rank Sum Test | N/A | N/A | 0.40 |
| Marijuana Craving Questionnaire, mean (SD){d} | ||||||
| Compulsion subscale | −Q4.50 (4.70) | −4.00 (4.72) | Wilcoxon Rank Sum Test | N/A | N/A | 0.97 |
| Emotion subscale | −5.25 (5.20) | −3.88 (4.74) | Wilcoxon Rank Sum Test | N/A | N/A | 0.43 |
| Expectancy subscale | −5.40 (4.47) | −5.84 (5.15) | Wilcoxon Rank Sum Test | N/A | N/A | 0.88 |
| Purposefulness subscale | −7.50 (5.61) | −5.08 (5.05) | Wilcoxon Rank Sum Test | N/A | N/A | 0.17 |
| Total score | −22.65 (16.29) | −19.40 (15.75) | Wilcoxon Rank Sum Test | N/A | N/A | 0.71 |
| Withdrawal checklist, mean (SD){d} | ||||||
| Total score | −10.87 (8.99) | −10.40 (7.73) | Wilcoxon Rank Sum Test | N/A | N/A | 0.99 |
{a}
Summaries represent model-based estimates from a generalized linear model using all available data.
{b}
For the Intention-to-Treat (ITT) analysis, the denominators were n=23 for Buspirone and n=27 for Placebo. Only observed results that were negative were considered
{d}
Values are change from baseline using last observation carried forward method of imputation. One placebo subject did not have any post baseline scale-based